Meeting
2021 ASCO Annual Meeting
Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).
Authors
Zerui Zhao
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, VA, China
Zerui Zhao , Si Chen , Han Qi , Chao-Pin Yang , Yao-Bin Lin , Jie-Tian Jin , Shan-Shan Lian , Yi-Zhi Wang , Hui Yu , Long Hao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04304248
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8541)
DOI
10.1200/JCO.2021.39.15_suppl.8541
Abstract #
8541
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Preliminary analysis of PD-1 inhibitors combined with chemotherapy as neoadjuvant therapy for local advanced non-small cell lung cancer (NSCLC).
First Author: Hongru Li
Poster
2024 ASCO Annual Meeting
Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.
First Author: Naixin Ding
Poster
2023 ASCO Annual Meeting
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).
First Author: Yaobin Lin
Poster
2023 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield